ASRS ’24: C1q Inhibition and Metformin for AMD

Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Dimitra Skondra, MD, fills us in on the latest research regarding potential interactions between metformin and AMD development in non-diabetic patients. Does the future of care include metformin as prophylaxis? Stick with us to find out.